02 · 파이프라인

39개 프로그램.

혁신신약 18 · 바이오시밀러 16 · 플랫폼 4 · 진단법 1. 단일 R&D 운영 위에서 모든 단계가 동시에 진행되며, PBP1510 (PAUF) Phase 1/2a · TUZNUE (HD201) EU 승인 · VASFORDA (HD204) BLA H2 2026이 핵심 모멘텀입니다.

Discovery

Pre-clinical / CLD / IND prep / PoC

Phase 1

Phase 1/2a

Phase 3

Approved

#코드적응증 / 표적모달리티단계지역업데이트

01PBP1510PDAC · PAUFHumanized IgG1 · 1st-in-classPhase 1/2aUS/KR2025.10

02PBP1710TNBC · 섬유증 · CTHRC1Human IgG1 · 1st-in-classPre-clinicalKR · K-NDP2025.12

03IDC007CRS · 전신 염증Bispecific AbCLDKR2026.02

04IDC331Solid tumorNovel Concept AbPoCKR—

05IDC332Solid tumorNovel Concept AbPoCKR—

06IDC333Solid tumorNovel Concept AbPoCKR—

07IDC334Solid tumorNovel Concept AbDiscoveryKR—

08IDC111Solid tumor1st-in-class AbDiscoveryKR—

09IDC112Solid tumor1st-in-class AbDiscoveryKR—

10IDC113Solid tumor1st-in-class AbDiscoveryKR—

11IDC114Immune disease1st-in-class AbDiscoveryKR—

12IDC115Immune disease1st-in-class AbDiscoveryKR—

13IDC441Solid tumorADCDiscoveryKR—

14IDC001Solid tumorBispecific AbDiscoveryKR—

15IDC002Solid tumorBispecific AbDiscoveryKR—

16IDC003Solid tumorBispecific AbDiscoveryKR—

17IDC008Solid tumorBispecific AbDiscoveryKR—

18IDC009Solid tumorBispecific AbDiscoveryKR—

19HD201 · TUZNUEOncology · Trastuzumab (Herceptin)BiosimilarApprovedEU · 50+ licensed2024.09

20HD204 · VASFORDANSCLC · Bevacizumab (Avastin)BiosimilarPhase 3 · BLA H2 2026Global2026.03

21PBP1502Auto-immune · Adalimumab (Humira)BiosimilarPhase 1EU/KR2026

22PBP1601Bone · Denosumab (Prolia)BiosimilarIND prep——

23PBP2101Oncology · Nivolumab (Opdivo)BiosimilarIND prep——

24PBP2102Oncology · Pembrolizumab (Keytruda)BiosimilarIND prep——

25PBP1603Rare · Eculizumab (Soliris)BiosimilarCLD——

26IDC2301Hematology · Emicizumab (Hemlibra)Bispecific biosimilarCLD——

27IDC2401Auto-immune · Ustekinumab (Stelara)BiosimilarCLD——

28IDC2402Endocrine · Dulaglutide (Trulicity)Biosimilar · GLP-1 RACLD——

29IDC2403MS · Ocrelizumab (Ocrevus)BiosimilarCLD——

30IDC2404IBD · Vedolizumab (Entyvio)BiosimilarCLD——

31IDC2405Oncology · Pertuzumab (Perjeta)BiosimilarCLD——

32IDC2501Atopy · Dupilumab (Dupixent)BiosimilarCLD——

33IDC2502Psoriasis · Risankizumab (Skyrizi)BiosimilarCLD——

34IDC2503Oncology · Atezolizumab (Tecentriq)BiosimilarCLD——

35IDC224Breast cancer · SC deliveryHydrogel SC platformPoCKR2026.04

36IDC225Ocular deliveryOcular platformDiscoveryKR—

37IDC226Arthritis · SCSC platformPoCKR—

38IDC227TASA™TASA platformPoCKR—

39IDC221Pancreatic cancer · PAUFIHC · ELISADiscoveryKR—

39 / 39 표시 · 출처: 회사 공식 자료